Two-phase II trials investigated a novel experimental medicine named VX-548 for lowering acute pain following abdominoplasty or bunionectomy surgery. VX-548 is a selective sodium channel blocker that is implicated in pain transmission. Patients receiving the maximum dose of VX-548 exhibited a statistically significant reduction in pain ratings compared to placebo in the studies; however, lesser doses were ineffective. The actual impact size of the greatest dose, on the other hand, was deemed insignificant. The majority of VX-548’s adverse effects were mild to moderate. Although the studies show preliminary evidence for this novel class of selective sodium channel blockers as a viable non-opioid alternative for immediate postoperative pain, multimodal therapy integrating diverse pain pathways is likely to be required for effective pain management.

To know more: About the original article click here.